BioXcel Therapeutics
Business Services · Connecticut, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
555 Long Wharf Dr Fl 12, New Haven, Conn...Phone Number
(475) 238-6837Website
www.bioxceltherapeutics.comRevenue
<$5 MillionStock Symbol
BTAIIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
1
1
About BioXcel Therapeutics
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The companys wholly owned, clinical-stage subsidiary, OnkosXcel Therapeutics, is focused on developing medicines in immuno-oncology.Explore more
BioXcel Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioXcel Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioXcel Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on BioXcel Therapeutics recently announced quarterly report
BioXcel Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when BioXcel Therapeutics launches new products
Check out if BioXcel Therapeutics is spiking on competitors!
Check if BioXcel Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if BioXcel Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once BioXcel Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined BioXcel Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to BioXcel Therapeutics
Compare insights from companies similar to BioXcel Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioXcel Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BioXcel Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BioXcel Therapeutics.
BioXcel Therapeutics financials insights
Gather financial insights about BioXcel Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$260M
BioXcel Therapeutics Tech Stack
A closer look at the technologies used by BioXcel Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Pharmaceuticals
Person-Based
Pharmaceuticals
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
BioXcel Therapeutics News & Media
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing ...
BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Agreement is part of a court-supervised sale process with BioXcel Therapeutics, Inc. and remains subject to bankruptcy court approval, potential higher bids, and customary closing conditions. Transaction reflects Teva’s targeted business development approach focused on strategic fit,Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
Teva Pharmaceuticals proposes acquiring BXCL501, expanding its neuroscience portfolio with a novel agitation treatment under FDA reviewBioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholdersBioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding BioXcel Therapeutics
Sign Up For FreeTo access detailed company insights
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The companys wholly owned, clinical-stage subsidiary, OnkosXcel Therapeutics, is focused on developing medicines in immuno-oncology.... Read More
